Wnt/β-Catenin Signaling and Immunotherapy Resistance: Lessons for the Treatment of Urothelial Carcinoma

Urothelial cell carcinoma (UCC) is a significant public health burden. It accounts for approximately 90 percent of all bladder cancers with an estimated 200,000 annual deaths globally. Platinum based cytotoxic chemotherapy combinations are the current standard of care in the frontline setting for me...

Full description

Saved in:
Bibliographic Details
Published in:Cancers 2021-02, Vol.13 (4), p.889
Main Authors: Chehrazi-Raffle, Alexander, Dorff, Tanya B, Pal, Sumanta K, Lyou, Yung
Format: Article
Language:English
Subjects:
Biomarkers
Bladder cancer
Cancer therapies
Chemotherapy
Clinical trials
Cytotoxicity
Deoxyribonucleic acid
DNA
Genes
Genomics
Immune checkpoint inhibitors
Immunotherapy
Metastases
Mutation
Patients
Platinum
Proteins
Public health
Review
Signal transduction
Tumors
Urothelial carcinoma
Wnt protein
β-Catenin
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Urothelial cell carcinoma (UCC) is a significant public health burden. It accounts for approximately 90 percent of all bladder cancers with an estimated 200,000 annual deaths globally. Platinum based cytotoxic chemotherapy combinations are the current standard of care in the frontline setting for metastatic UCC. Even with these treatments the median overall survival is estimated to be about 15 months. Recently, immune checkpoint inhibitors (ICIs) have demonstrated superior clinical benefits compared to second line chemotherapy in UCC treatment. However only a minority of patients (~20%) respond to ICIs, which highlights the need to better understand the mechanisms behind resistance. In this review, we (i) examine the pathophysiology of Wnt/β-catenin signaling, (ii) discuss pre-clinical evidence that supports the combination of Wnt/β-catenin inhibitors and ICI, and (iii) propose future combination treatments that could be investigated through clinical trials.
ISSN:2072-6694
2072-6694
DOI:10.3390/cancers13040889